- Home
- MNKD vs AIAI Comparison
MNKD vs AIAI Comparison
Compare MNKD & AIAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNKD | AIAI |
|---|---|---|
| Founded | 1991 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MNKD | AIAI |
|---|---|---|
| Price | $3.95 | $3.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.97 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 462.3K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $27.07 | N/A |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $3.03 |
| 52 Week High | $6.51 | $18.88 |
Technical Indicators
Market Signals| Indicator | MNKD | AIAI |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 40.91 |
| Support Level | $3.77 | $3.19 |
| Resistance Level | $4.29 | $4.29 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | 0.05 | 0.10 |
| Stochastic Oscillator | 90.05 | 16.18 |
Price Performance
Historical ComparisonAbout MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.